AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7756106 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase NAT1 activity in cystic fibrosis patients (n = 4)
Number of subjects: 39
Study 7756106 — intervention group
Group type: COMPARATOR
Intervention: N-acetyltransferase NAT1 activity in control subjects (n = 9)
Number of subjects: 39
Study 7756106 — intervention group
Group type: EXPERIMENTAL
Intervention: Km and Vmax values of NAT1 in MNL from CF patients
Number of subjects: 39
Study 7756106 — intervention group
Group type: COMPARATOR
Intervention: Km and Vmax values of NAT1 in MNL from control subjects
Number of subjects: 39
Study 2258378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (145 mg daily)
Number of subjects: 149
Study 2258378 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (104 mg daily)
Number of subjects: 149
Study 2258378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 6795614 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg cefuroxime i.m. with premedication and then 8 hourly for 3 days (group A)
Number of subjects: 114
Study 6795614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime i.v. at the time of induction of anaesthesia (group B)
Number of subjects: 114
Study 6795614 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group C)
Number of subjects: 114
Study 31740387 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 55
Study 31740387 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 PUFA supplementation
Number of subjects: 55
Study 31484559 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic acupuncture (BA)
Number of subjects: 32
Study 31484559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint specificity (AS)
Number of subjects: 32
Study 31484559 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle duration (ND)
Number of subjects: 32
Study 31484559 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 32
Study 27986838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornstarch-based gel
Number of subjects: 34
Study 27986838 — intervention group
Group type: COMPARATOR
Intervention: Commercial gel
Number of subjects: 34
Study 25378208 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weightbearing (AWB) group allowed full weightbearing after 6 weeks
Number of subjects: 31
Study 25378208 — intervention group
Group type: COMPARATOR
Intervention: Delayed weightbearing (DWB) group allowed full weightbearing after 10 weeks
Number of subjects: 31
Study 25378208 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based variables (bone edema, effusion) and KOOS
Number of subjects: 31
Study 23910063 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg orally before ERCP
Number of subjects: 483
Study 23910063 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally before ERCP
Number of subjects: 483
Study 21763472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged expiration breathing (2-s inspired time and 4-s expired time)
Number of subjects: 11
Study 21763472 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing without any constraints
Number of subjects: 11
Study 19499864 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB-guided PLMA insertion
Number of subjects: 96
Study 19499864 — intervention group
Group type: COMPARATOR
Intervention: Introducer tool technique
Number of subjects: 96
Study 19499864 — intervention group
Group type: COMPARATOR
Intervention: Digital technique
Number of subjects: 96
Study 16428482 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of p95HER-2 in primary tumor tissue
Number of subjects: 483
Study 16428482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of p95HER-2 in primary tumor tissue
Number of subjects: 483
Study 16428482 — intervention group
Group type: COMPARATOR
Intervention: High levels of p185HER-2
Number of subjects: 483
Study 16428482 — intervention group
Group type: EXPERIMENTAL
Intervention: High p95HER-2
Number of subjects: 483
Study 15603203 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of pure histamine (equaling 124 mg histamine dihydrochloride, dissolved in peppermint tea)
Number of subjects: 10
Study 15603203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (peppermint tea)
Number of subjects: 10
Study 11730650 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 39
Study 9078931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of vocal cord function
Number of subjects: 27
Study 8102552 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg/day
Number of subjects: 33
Study 8102552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2884860 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 54
Study 2884860 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 54
Study 31147478 — intervention group
Group type: EXPERIMENTAL
Intervention: $30 per call for taking up to five Wisconsin Tobacco Quit Line (WTQL) calls
Number of subjects: 1900
Study 31147478 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 per call for the first four WTQL calls and $70 for the fifth WTQL call
Number of subjects: 1900
Study 31147478 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable payments with $20 for the first four calls and $70 for the fifth call
Number of subjects: 1900
Study 31147478 — intervention group
Group type: COMPARATOR
Intervention: Control group received $0 per call
Number of subjects: 1900
Study 30371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP <130 mm Hg
Number of subjects: 5380
Study 30371278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP <80 mm Hg
Number of subjects: 5380
Study 30371278 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP 131 to 140 mm Hg (reference group)
Number of subjects: 5380
Study 30371278 — intervention group
Group type: COMPARATOR
Intervention: Diastolic BP 81 to 90 mm Hg (reference group)
Number of subjects: 5380
Study 27030562 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy using the Multi Joint System (MJS) device for 40 min, 5 days/week for 3 weeks, in addition to standard therapeutic physical exercises, massage, laser and pulsed current therapy.
Number of subjects: 52
Study 27030562 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic physical exercises, massage, laser and pulsed current therapy (control group).
Number of subjects: 52
Study 25996101 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent neoadjuvant chemoradiotherapy (XELOX regimen)
Number of subjects: 76
Study 25996101 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 76
Study 23213070 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg or 300 mg)
Number of subjects: 73
Study 23213070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21788967 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg) plus tolterodine SR (4 mg)
Number of subjects: 176
Study 21788967 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (4 mg) plus placebo
Number of subjects: 176
Study 19880460 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR*D intervention (medication switching and augmentation)
Number of subjects: 0
Study 16391588 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol 200 mg and ascorbic acid 100 mg twice daily
Number of subjects: 174
Study 15349657 — intervention group
Group type: EXPERIMENTAL
Intervention: Coptis root membrane
Number of subjects: 30
Study 15349657 — intervention group
Group type: COMPARATOR
Intervention: Iodine glycerin
Number of subjects: 30
Study 15349657 — intervention group
Group type: COMPARATOR
Intervention: Single drug membrane
Number of subjects: 30
Study 15349657 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 30
Study 10940443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 10940443 — intervention group
Group type: COMPARATOR
Intervention: Control group (responders)
Number of subjects: 0
Study 9279492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine Stimuli Condition (0.4 mg/kg delivery of cocaine)
Number of subjects: 10
Study 9279492 — intervention group
Group type: COMPARATOR
Intervention: Neutral Stimuli Condition (placebo, 5 mg)
Number of subjects: 10
Study 8333814 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Number of subjects: 587
Study 8333814 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 587
Study 8333814 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 587
Study 8333814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 25 mg/d
Number of subjects: 587
Study 8333814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg/d
Number of subjects: 587
Study 2906255 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine (E) HCl in capsules, ascending doses at 72‐h intervals
Number of subjects: 12
Study 29206721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 251
Study 29206721 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir‐boosted atazanavir (ATV/r)
Number of subjects: 251
Study 28790056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic chlorhexidine (0.5% chlorhexidine in 70% ethanol)
Number of subjects: 916
Study 28790056 — intervention group
Group type: COMPARATOR
Intervention: Aqueous chlorhexidine (0.5% chlorhexidine aqueous solution)
Number of subjects: 916
Study 28790056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 916
Study 26286128 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Cancer and Living Meaningfully (CALM) intervention group (IG)
Number of subjects: 0
Study 26286128 — intervention group
Group type: COMPARATOR
Intervention: Usual non-manualized supportive psycho-oncological intervention (SPI) control group (CG)
Number of subjects: 0
Study 23743161 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Qingli formula treatment in combination with Western medicine
Number of subjects: 60
Study 23743161 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with Western medicine
Number of subjects: 60
Study 21443586 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tablets
Number of subjects: 39
Study 21443586 — intervention group
Group type: EXPERIMENTAL
Intervention: Jellybeans
Number of subjects: 39
Study 21443586 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 39
Study 21443586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar mints (Mentos dragees®)
Number of subjects: 39
Study 18959452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' singing (recorded singing songs of their choice for use at home, played 20 minutes per day, 3 to 5 times per week)
Number of subjects: 90
Study 18959452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no singing intervention)
Number of subjects: 90
Study 16856623 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha2a (180 microg/week) plus RBV (800mg/day)
Number of subjects: 34
Study 16856623 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha2b (1.5 microg/kg/week) plus RBV (800‐1,200mg/day)
Number of subjects: 34
Study 16856623 — intervention group
Group type: EXPERIMENTAL
Intervention: VOSE group
Number of subjects: 34
Study 15676315 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 25
Study 15676315 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 25
Study 10935680 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 504
Study 8708519 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis
Number of subjects: 46
Study 8708519 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 46
Study 1855729 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified PMMA IOL
Number of subjects: 53
Study 1855729 — intervention group
Group type: COMPARATOR
Intervention: Regular PMMA lenses (Control)
Number of subjects: 53
Study 7042110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2.0 g i.v. on admission and 2.0 g i.v. 3 hours later)
Number of subjects: 40
Study 7042110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical schedule as methylprednisolone)
Number of subjects: 40
Study 7042110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 40
Study 7042110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7042110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Placebo
Number of subjects: 40
Study 31755803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 554
Study 31755803 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment (Group A)
Number of subjects: 554
Study 31755803 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 554
Study 31060544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy, CRS and HIPEC after 3-4 cycles of systemic chemotherapy
Number of subjects: 106
Study 31060544 — intervention group
Group type: COMPARATOR
Intervention: Palliative systemic chemotherapy only
Number of subjects: 106
Study 28643618 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stabilised rice bran (30 g/d)
Number of subjects: 19
Study 28643618 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional ingredient)
Number of subjects: 19
Study 26056862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oriental medicine music therapy (OMMT)
Number of subjects: 30
Study 26056862 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 23361061 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT)
Number of subjects: 21
Study 23361061 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 21391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving-window method for examining continuous covariates and missing IVUS values
Number of subjects: 0
Study 21391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF) method for imputing lipid endpoints
Number of subjects: 0
Study 21391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation approach for missing covariates
Number of subjects: 0
Study 21391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified key contributors to missing IVUS endpoint
Number of subjects: 0
Study 18539337 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase cognitive therapy (C‐CT) for 8 months
Number of subjects: 84
Study 18539337 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 84
Study 18539337 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐CT
Number of subjects: 84
Study 17463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 0
Study 17463374 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 0
Study 15510599 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (500 mg b.i.d)
Number of subjects: 19
Study 15510599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11566517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroview IOL (Storz Hydroview H60M)
Number of subjects: 60
Study 11566517 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOL (Storz P497UV)
Number of subjects: 60
Study 9562365 — intervention group
Group type: EXPERIMENTAL
Intervention: CrH2O (4 x 5 g of CrH2O and 1 g glucose/day)
Number of subjects: 15
Study 9562365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 x 6 g of glucose/day)
Number of subjects: 15
Study 7886408 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoretroperitoneal approach with saphenous vein bypass grafting
Number of subjects: 16
Study 7886408 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal approach with Dacron prosthesis
Number of subjects: 16
Study 3346979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234
Study 3346979 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study 3346979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (in smokers)
Number of subjects: 3234
Study 30893169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinumtoxin A
Number of subjects: 0
Study 30893169 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinumtoxin A
Number of subjects: 0
Study 29110679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg body-weight of gadobutrol
Number of subjects: 60
Study 29110679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg body-weight of gadobutrol
Number of subjects: 60
Study 29110679 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadobutrol
Number of subjects: 60
Study 25788173 — intervention group
Group type: EXPERIMENTAL
Intervention: Band and loop (B&L) space maintainers
Number of subjects: 36
Study 25788173 — intervention group
Group type: COMPARATOR
Intervention: Crown and loop (C&L) space maintainers
Number of subjects: 36
Study 23306828 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg retinal tomography (HRT) 3
Number of subjects: 117
Study 23306828 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology (FDT) perimetry
Number of subjects: 117
Study 21500240 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression Discontinuity Design (RDD)
Number of subjects: 0
Study 21500240 — intervention group
Group type: COMPARATOR
Intervention: Traditional Group Randomized Trial (GRT)
Number of subjects: 0
Study 18652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with inductance coupling treatment
Number of subjects: 60
Study 18652323 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 60
Study 16827023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay restoration
Number of subjects: 120
Study 16827023 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay with only lingual cuspal coverage
Number of subjects: 120
Study 16827023 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay with buccal and palatal cuspal coverage
Number of subjects: 120
Study 16827023 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth (control group)
Number of subjects: 120
Study 16827023 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mm diameter steel ball
Number of subjects: 120
Study 16827023 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mm diameter steel ball
Number of subjects: 120
Study 12837183 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusion resuscitation
Number of subjects: 20
Study 12837183 — intervention group
Group type: COMPARATOR
Intervention: Plasma resuscitation
Number of subjects: 20
Study 10751520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (PET,O2 55 mmHg; 7.3 kPa)
Number of subjects: 6
Study 10751520 — intervention group
Group type: COMPARATOR
Intervention: Control (continued euoxia; PET,O2 100 mmHg; 13.3 kPa)
Number of subjects: 6
Study 8601116 — intervention group
Group type: COMPARATOR
Intervention: Active treatment
Number of subjects: 0
Study 8601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for calculations
Number of subjects: 0
Study 8601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions
Number of subjects: 0
Study 8601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 0
Study 8601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Time periods
Number of subjects: 0
Study 1536482 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 12
Study 1536482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 12
Study 1536482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 12
Study 1536482 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 12
Study 1536482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 12
Study 6233093 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 20
Study 6233093 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 20
Study 30879395 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor intervention (ABC learning approach)
Number of subjects: 45
Study 30879395 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor intervention (ABC learning approach) + regular educational services
Number of subjects: 45
Study 30879395 — intervention group
Group type: COMPARATOR
Intervention: Regular educational services
Number of subjects: 45
Study 30146141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with homework completion after Sessions 2 and 3
Number of subjects: 140
Study 30146141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with homework completion after Sessions 8 and 9
Number of subjects: 140
Study 30146141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) in the second half of treatment
Number of subjects: 140
Study 25057809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 0
Study 25057809 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid diet
Number of subjects: 0
Study 25057809 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet with n-3 polyunsaturated fatty acids
Number of subjects: 0
Study 25057809 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet with placebo
Number of subjects: 0
Study 22761409 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of voriconazole
Number of subjects: 110
Study 22761409 — intervention group
Group type: COMPARATOR
Intervention: Non-therapeutic drug monitoring (non-TDM) of voriconazole
Number of subjects: 110
Study 20465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 20